MACH14: A multi-site collaboration on ART adherence among 14 institutions

AIDS and Behavior

Volumn 17, Issue 1, 2013, Pages 127-141

  Liu, Honghu ^a   Wilson, Ira B ^b   Goggin, Kathy ^c   Reynolds, Nancy ^d   Simoni, Jane M ^e   Golin, Carol E ^f   Rosen, Marc I ^g   Gross, Robert ^h   Wagner, Glenn ⁱ   Remien, Robert H ^j   Schneiderman, Neil ^k   Erlen, Judith A ^l   Arnsten, Julia H ^m   Bangsberg, David R ⁿ  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF MISSOURI KANSAS CITY   (United States)

^d YALE UNIVERSITY   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF PENNSYLVANIA   (United States)

ⁱ RAND CORPORATION   (United States)

^j NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

^k University of Miami   (United States)

^l UNIVERSITY OF PITTSBURGH   (United States)

^m ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁿ MASSACHUSETTS GENERAL HOSPITAL   (United States)

more..

Author keywords

Adherence; Antiretroviral medication; HIV AIDS; Individual participant data; MEMS; Multi site

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADOLESCENT; ADULT; AGED; CLINICAL TRIAL (TOPIC); COOPERATION; DRUG EFFECT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFORMATION PROCESSING; INFORMATION SYSTEM; MALE; METHODOLOGY; MIDDLE AGED; MULTICENTER STUDY; PATIENT COMPLIANCE; PSYCHOLOGICAL ASPECT; REVIEW; SOCIOECONOMICS; STATISTICS; VIROLOGY; VIRUS LOAD;

ADOLESCENT; ADULT; AGED; ANTI-HIV AGENTS; CLINICAL TRIALS AS TOPIC; COOPERATIVE BEHAVIOR; DATA COLLECTION; FEMALE; HIV INFECTIONS; HUMANS; INFORMATION SYSTEMS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; SOCIOECONOMIC FACTORS; VIRAL LOAD; YOUNG ADULT;

MLCS; MLOWN;

EID: 84872682148     PISSN: 10907165     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10461-012-0272-4     Document Type: Article

References (28)

1. Feeney ER, Mallon PWG. HIV and HAART-associated dyslipidemia. Open Cardiovasc Med J. 2011;5:49-63.
2. Enanoria WTA, Ng C, Saha SR, Colford JM Jr. Treatment outcomes after highly active antiretroviral therapy: a meta-analysis of randomised controlled trials. Lancet Infect Dis. 2004;4(7):414-25.
3. Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA. 2008;300(1):51-9.
4. Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14(4):357-66.
5. Lucas GM. Antiretroviral adherence, drug resistance, viral fitness and HIV disease progression: a tangled web is woven. J Antimicrob Chemother. 2005;55(4):413-6.
6. Chen LF, Hoy J, Lewin SR. Ten years of highly active antiretroviral therapy for HIV infection. Med J Aust. 2007;186(3):146-51.
7. Liu H, Golin CE, Miller LG, et al. A comparison study of multiple measures of adherence to HIV protease inhibitors. Ann Intern Med. 2001;134(10):968-77.
8. Reynolds NR. Adherence to antiretroviral therapies: state of the science. Curr HIV Res. 2004;2(3):207-14.
9. Pearson CR, Simoni JM, Hoff P, Kurth AE, Martin DP. Assessing antiretroviral adherence via electronic drug monitoring and self-report: an examination of key methodological issues. AIDS Behav. 2007;11(2):161-73.
10. Wagner GJ. Predictors of antiretroviral adherence as measured by self-report, electronic monitoring, and medication diaries. AIDS Patient Care STD. 2002;16(12):599-608.
11. Wagner G. Placebo practice trials: the best predictor of adherence readiness for HAART among drug users? HIV Clinical Trials. 2003;4(4):269-81.
12. Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. J Acquir Immune Defic Syndr. 2006;43(Suppl 1):S79-87.
13. Levine AJ, Hinkin CH, Marion S, et al. Adherence to antiretroviral medications in HIV: differences in data collected via self-report and electronic monitoring. Health Psychol. 2006;25(3):329-35.
14. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in Southern African adults. AIDS. 2008;22(16):2117-25.
15. Rivet Amico K, Harman JJ, Johnson BT. Efficacy of antiretroviral therapy adherence interventions: a research synthesis of trials, 1996 to 2004. JAIDS J Acq Immune Defic Syndr. 2006;41(3):285-297.
16. Konkle-Parker DJ, Erlen JA, Dubbert PM. Lessons learned from an HIV adherence pilot study in the Deep South. Patient Educ Couns. 2010;78(1):91-6.
17. Giordano TP, Guzman D, Clark R, Charlebois ED, Bangsberg DR. Measuring adherence to antiretroviral therapy in a diverse population using a visual analogue scale. HIV Clin Trials. 2004;5(2):74-9.
18. Pinheiro JC, Bates DM. Mixed-effects models in S and S-PLUS. New York: Springer; 2009.
19. Teramukai S, Matsuyama Y, Mizuno S, Sakamoto J. Individual patient-level and study-level meta-analysis for investigating modifiers of treatment effect. Jpn J Clin Oncol. 2004;34(12):717-21.
20. Jones AP, Riley RD, Williamson PR, Whitehead A. Meta-analysis of individual patient data versus aggregate data from longitudinal clinical trials. Clin Trials. 2009;6(1):16.
21. Lambert PC, Sutton AJ, Abrams KR, Jones DR. A comparison of summary patient-level covariates in meta-regression with individual patient data meta-analysis. J Clin Epidemiol. 2002;55(1):86-94.
22. Cooper H, Patall EA. The relative benefits of meta-analysis conducted with individual participant data versus aggregated data. Psychol Methods. 2009;14(2):165-76.
23. Liu H, Miller LG, Hays RD, et al. A practical method to calibrate self-reported adherence to antiretroviral therapy. JAIDS J Acq Immune Defic Syndr. 2006;43:S104-12.
24. Liu H, Miller LG, Hays RD, et al. Repeated measures longitudinal analyses of HIV virologic response as a function of percent adherence, dose timing, genotypic sensitivity, and other factors. JAIDS J Acq Immune Defic Syndr. 2006;41(3):315-22.
25. Little RJA, Rubin DB. Statistical analysis with missing data. 2nd ed. New York: Wiley-Interscience; 2002.
26. Schafer JL, Graham JW. Missing data: our view of the state of the art. Psychol Methods. 2002;7(2):147-77.
27. Collins LM, Schafer JL, Kam CM. A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods. 2001;6(4):330-51.
28. Newgard CD, Haukoos JS. Advanced statistics: missing data in clinical research - part 2: multiple imputation. Acad Emerg Med. 2007;14(7):669-78.